Title : Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy.

Pub. Date : 2016

PMID : 27895464






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Selexipag, a novel, oral prostacyclin receptor agonist, has been shown to improve hemodynamics in a phase II clinical trial and reduce clinical worsening in a large phase III clinical trial involving patients with pulmonary arterial hypertension. selexipag prostaglandin I2 receptor Homo sapiens